Lipaglyn™ is a First-in-class drug targeted at bridging an unmet healthcare need for
treating Diabetic Dyslipidemia or Hypertriglyceridemia in type 2 diabetes, not
controlled by statins alone.
Lipaglyn™, a once-daily, oral drug, recommended in strength of 4 mg, has been rationally designed to have high specificity of PPAR-alpha and moderate activity on PPAR-gamma receptors to optimize beneficial effects on lipids and
glycemic control and without any safety concerns.
Lipaglyn™, a non-thiazolidinedione, has a novel action with an excellent safety
profile. It provides the benefits of both ‘fibrates’ and ‘glitazones’ in a single drug
without their side effects (no CV adverse events, no weight gain, no potential for
edema, no potential for liver, kidney and muscle toxicity).
